|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.640 USD | +0.76% |
|
+1.93% | -16.19% |
| Capitalization | 1.36B 1.16B 1.08B 1.02B 1.87B 124B 2.05B 12.66B 4.88B 58.26B 5.12B 5.01B 211B | P/E ratio 2025 * |
-15.3x | P/E ratio 2026 * | -104x |
|---|---|---|---|---|---|
| Enterprise value | 1.2B 1.02B 957M 897M 1.66B 109B 1.81B 11.18B 4.31B 51.43B 4.52B 4.42B 186B | EV / Sales 2025 * |
0.63x | EV / Sales 2026 * | 0.43x |
| Free-Float |
75.33% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Clover Health Investments, Corp.
| 1 day | +0.76% | ||
| 1 week | +1.93% | ||
| Current month | +6.02% | ||
| 1 month | +6.88% | ||
| 3 months | -15.38% | ||
| 6 months | -9.59% | ||
| Current year | -16.19% |
| 1 week | 2.58 |  | 2.8 |
| 1 month | 2.16 | | 2.8 |
| Current year | 2.12 | | 4.87 |
| 1 year | 2.12 | | 4.87 |
| 3 years | 0.61 | | 4.87 |
| 5 years | 0.61 | | 28.85 |
| 10 years | 0.61 | | 28.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andrew Toy
CEO | Chief Executive Officer | 46 | 2022-12-31 |
Peter Kuipers
DFI | Director of Finance/CFO | 53 | 2024-05-06 |
Conrad Wai
CTO | Chief Tech/Sci/R&D Officer | 44 | 2022-02-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Garipalli
CHM | Chairman | 46 | 2022-12-31 |
Andrew Toy
BRD | Director/Board Member | 46 | 2018-10-31 |
William Robinson
BRD | Director/Board Member | 60 | 2021-03-24 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.02% | 324 M€ | +8.37% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.76% | +1.93% | -15.38% | +149.06% | 1.36B | |
| -2.02% | +3.28% | -32.96% | -36.18% | 303B | |
| -2.43% | +6.70% | -5.73% | -29.91% | 78.21B | |
| -0.38% | +5.10% | +1.04% | -15.64% | 73.76B | |
| -6.03% | +3.10% | -0.88% | -48.73% | 31.05B | |
| -3.66% | +2.34% | -34.14% | -52.13% | 19.15B | |
| -3.38% | +2.55% | -45.55% | -51.96% | 8.27B | |
| -0.40% | +4.27% | +78.68% | +71.78% | 4.01B | |
| -1.25% | +5.22% | +74.68% | -18.28% | 2.24B | |
| -2.48% | -7.37% | -26.84% | - | 370M | |
| Average | -0.83% | +2.77% | -0.71% | -3.55% | 52.12B | |
| Weighted average by Cap. | -0.55% | +4.00% | -21.02% | -32.52% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.9B 1.62B 1.51B 1.42B 2.62B 173B 2.87B 17.67B 6.82B 81.3B 7.14B 6.99B 295B | 2.62B 2.23B 2.08B 1.95B 3.6B 238B 3.95B 24.33B 9.39B 112B 9.83B 9.63B 406B |
| Net income | -88.48M -75.14M -70.3M -65.89M -122M -8.04B -133M -821M -317M -3.78B -332M -325M -13.7B | -12.48M -10.6M -9.92M -9.3M -17.16M -1.13B -18.8M -116M -44.7M -533M -46.82M -45.84M -1.93B |
| Net Debt | -160M -136M -127M -119M -220M -14.53B -241M -1.48B -572M -6.82B -599M -587M -24.74B | -234M -198M -186M -174M -321M -21.24B -352M -2.17B -837M -9.98B -876M -858M -36.17B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 2.640 $ | +0.76% | 2,905,768 |
| 25-12-15 | 2.620 $ | -2.96% | 4,584,988 |
| 25-12-12 | 2.700 $ | -1.82% | 3,474,398 |
| 25-12-11 | 2.750 $ | +3.38% | 4,315,849 |
| 25-12-10 | 2.660 $ | +2.70% | 4,402,096 |
Delayed Quote Nasdaq, December 16, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CLOV Stock
Select your edition
All financial news and data tailored to specific country editions
